173 related articles for article (PubMed ID: 25641594)
1. Heterologous expression of carcinoembryonic antigen in Lactococcus lactis via LcsB-mediated surface displaying system for oral vaccine development.
Zhang X; Hu S; Du X; Li T; Han L; Kong J
J Microbiol Immunol Infect; 2016 Dec; 49(6):851-858. PubMed ID: 25641594
[TBL] [Abstract][Full Text] [Related]
2. Expression of the capsid protein of porcine circovirus type 2 in Lactococcus lactis for oral vaccination.
Wang K; Huang L; Kong J; Zhang X
J Virol Methods; 2008 Jun; 150(1-2):1-6. PubMed ID: 18406475
[TBL] [Abstract][Full Text] [Related]
3. Expression of hepatitis B virus surface antigen determinants in Lactococcus lactis for oral vaccination.
Zhang Q; Zhong J; Huan L
Microbiol Res; 2011 Feb; 166(2):111-20. PubMed ID: 20227266
[TBL] [Abstract][Full Text] [Related]
4. Heterologous protein display on the cell surface of lactic acid bacteria mediated by the s-layer protein.
Hu S; Kong J; Sun Z; Han L; Kong W; Yang P
Microb Cell Fact; 2011 Oct; 10():86. PubMed ID: 22035337
[TBL] [Abstract][Full Text] [Related]
5. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
6. Oral vaccine of Lactococcus lactis harbouring pandemic H1N1 2009 haemagglutinin1 and nisP anchor fusion protein elevates anti-HA1 sIgA levels in mice.
Joan SS; Pui-Fong J; Song AA; Chang LY; Yusoff K; AbuBakar S; Rahim RA
Biotechnol Lett; 2016 May; 38(5):793-9. PubMed ID: 26758876
[TBL] [Abstract][Full Text] [Related]
7. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
Aarts WM; Schlom J; Hodge JW
Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
[TBL] [Abstract][Full Text] [Related]
8. Construction of a recombinant Lactococcus lactis strain expressing a fusion protein of Omp22 and HpaA from Helicobacter pylori for oral vaccine development.
Zhang R; Duan G; Shi Q; Chen S; Fan Q; Sun N; Xi Y
Biotechnol Lett; 2016 Nov; 38(11):1911-1916. PubMed ID: 27406731
[TBL] [Abstract][Full Text] [Related]
9. Oral immunization of mice with recombinant Lactococcus lactis expressing Cu,Zn superoxide dismutase of Brucella abortus triggers protective immunity.
Sáez D; Fernández P; Rivera A; Andrews E; Oñate A
Vaccine; 2012 Feb; 30(7):1283-90. PubMed ID: 22222868
[TBL] [Abstract][Full Text] [Related]
10. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
Lei H; Peng X; Jiao H; Zhao D; Ouyang J
Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
[TBL] [Abstract][Full Text] [Related]
11. Expression of a hepatitis A virus antigen in Lactococcus lactis and Escherichia coli and evaluation of its immunogenicity.
Berlec A; Malovrh T; Zadravec P; Steyer A; Ravnikar M; Sabotič J; Poljšak-Prijatelj M; Štrukelj B
Appl Microbiol Biotechnol; 2013 May; 97(10):4333-42. PubMed ID: 23371298
[TBL] [Abstract][Full Text] [Related]
12. Cell surface display system for Lactococcus lactis: a novel development for oral vaccine.
Raha AR; Varma NR; Yusoff K; Ross E; Foo HL
Appl Microbiol Biotechnol; 2005 Jul; 68(1):75-81. PubMed ID: 15635459
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and therapeutic efficacy of a dual-component genetic cancer vaccine cotargeting carcinoembryonic antigen and HER2/neu in preclinical models.
Aurisicchio L; Peruzzi D; Koo G; Wei WZ; La Monica N; Ciliberto G
Hum Gene Ther; 2014 Feb; 25(2):121-31. PubMed ID: 24195644
[TBL] [Abstract][Full Text] [Related]
14. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme.
Phuong LK; Allen C; Peng KW; Giannini C; Greiner S; TenEyck CJ; Mishra PK; Macura SI; Russell SJ; Galanis EC
Cancer Res; 2003 May; 63(10):2462-9. PubMed ID: 12750267
[TBL] [Abstract][Full Text] [Related]
15. Production of a particulate hepatitis C vaccine candidate by an engineered Lactococcus lactis strain.
Parlane NA; Grage K; Lee JW; Buddle BM; Denis M; Rehm BH
Appl Environ Microbiol; 2011 Dec; 77(24):8516-22. PubMed ID: 21984246
[TBL] [Abstract][Full Text] [Related]
16. Development of a new DNA vaccine based on mycobacterial ESAT-6 antigen delivered by recombinant invasive Lactococcus lactis FnBPA+.
Pereira VB; Saraiva TD; Souza BM; Zurita-Turk M; Azevedo MS; De Castro CP; Mancha-Agresti P; Dos Santos JS; Santos AC; Faria AM; Leclercq S; Azevedo V; Miyoshi A
Appl Microbiol Biotechnol; 2015 Feb; 99(4):1817-26. PubMed ID: 25503506
[TBL] [Abstract][Full Text] [Related]
17. DNA vaccine expressing repeated carcinoembryonic antigen (CEA)(625-667) induces strong immunity in mice.
Li D; Hua S; Fan Y; Xu S; Duan X; Liu L; Che Y; Li S; Tan Y
Immunol Lett; 2011 Mar; 135(1-2):124-8. PubMed ID: 21073899
[TBL] [Abstract][Full Text] [Related]
18. Secretory expression of K88 (F4) fimbrial adhesin FaeG by recombinant Lactococcus lactis for oral vaccination and its protective immune response in mice.
Hu CX; Xu ZR; Li WF; Niu D; Lu P; Fu LL
Biotechnol Lett; 2009 Jul; 31(7):991-7. PubMed ID: 19277476
[TBL] [Abstract][Full Text] [Related]
19. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects.
Grosenbach DW; Barrientos JC; Schlom J; Hodge JW
Cancer Res; 2001 Jun; 61(11):4497-505. PubMed ID: 11389081
[TBL] [Abstract][Full Text] [Related]
20. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus.
Kass E; Schlom J; Thompson J; Guadagni F; Graziano P; Greiner JW
Cancer Res; 1999 Feb; 59(3):676-83. PubMed ID: 9973217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
